Related Experiment Video
Updated: Jun 29, 2026
11:12
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
Published on: July 16, 2014
Intrabody and Parkinson's disease.
1Department of Neurology, Columbia University, New York, NY 10032, USA.
Biochimica Et Biophysica Acta
|October 7, 2008
Summary
Intrabody technology offers a novel therapeutic approach for incurable diseases like Parkinson's. This review explores intrabodies targeting alpha-synuclein and leucine-rich repeat kinase 2 for potential Parkinson's disease treatments.
Area of Science:
- Biotechnology
- Neuroscience
- Immunology
Background:
- Intrabody technology involves intracellular gene-engineered antibodies to modulate intracellular molecules.
- Parkinson's disease (PD) is a neurodegenerative disorder lacking a definitive cure.
- Alpha-synuclein (alpha-syn) misfolding is implicated in familial PD, presenting a therapeutic target.
Purpose of the Study:
- To review the origin, production, and therapeutic mechanisms of intrabodies.
- To assess the potential of intrabodies in combating alpha-synuclein toxicity in PD.
- To propose intrabody applications targeting leucine-rich repeat kinase 2 (LRRK2) mutations in PD.
Main Methods:
- Literature review on intrabody technology and its applications.
- Analysis of studies investigating intrabodies against alpha-synuclein.
- Exploration of potential intrabody strategies for LRRK2-related PD.
Main Results:
- Intrabodies demonstrate promise for intracellular therapeutic applications.
- Intrabodies can target misfolded proteins like alpha-synuclein.
- LRRK2 mutations are a significant genetic factor in PD, suggesting a target for intrabody intervention.
Conclusions:
- Intrabody technology represents a viable strategy for treating intracellular pathologies.
- Targeting alpha-synuclein with intrabodies offers a potential therapeutic avenue for PD.
- Intrabodies targeting LRRK2 present a novel approach for familial and sporadic Parkinson's disease.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:37Neural Regulation
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
01:11Alterations in Muscle Tone lll
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...